Imaging analysis software company Elucid announced today that it moved its headquarters to Boston’s Back Bay neighborhood.
The company moved to a modern space at 399 Boylston Street as it prepares to commercialize its flagship AI-powered plaque analysis software. It previously set up shop about a quarter-mile up the road at 2 Park Plaza in Boston.
Elucid’s move to new headquarters follows significant fundraising conducted over the past two years. The company raised $80 million in a Series C funding round last fall, adding to a $27 million Series B raised in 2022. It earmarked the funding to help further commercialization and expansion.
As part of a ramp-up for commercial launch, which includes hiring additional employees, Elucid sought out a new space. The new facility spans more than 16,000 square feet. The company aims for the new headquarters to provide room to grow, encourage collaboration and prioritize employee wellness.
Elucid develops the first histology-validated FDA-cleared software to non-invasively quantify and characterize non-calcified plaque and its components such as lipid-rich necrotic core (LRNC), giving potential insights into high-risk plaques, key drivers of risk of heart attack and stroke. It also aims to garner an indication for non-invasive measurement of fractional flow reserve (FFRCT).
“This new office space feels like a perfect fit for the Elucid team,” said Amy Kruglak, VP of people, Elucid. “This new environment will foster stronger team connections and enhance our collaborative efforts, bringing our hybrid workforce together more effectively to develop and deliver meaningful products that improve patient care. It also provides the necessary seating and infrastructure to support our three-year strategic plan.”
